Evaluation of Icotinib as a Potent and Selective Inhibitor of Aldehyde Oxidase for Reaction Phenotyping in Human Hepatocytes
- 2 April 2024
- journal article
- research article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 52 (6) , 565-573
Abstract
Aldehyde oxidase (AO) is a molybdenum cofactor-containing cytosolic enzyme that has gained prominence due to its involvement in the developmental failure of several drug candidates in first-in-human trials. Unlike cytochrome P450s (P450) and glucuronosyltransferase, AO substrates have been plagued by poor in vitro to in vivo extrapolation, leading to low systemic exposures and underprediction of human dose. However, apart from measuring a drug9s AO clearance rates, it is also important to determine the relative contribution to metabolism by this enzyme (fm,AO). Although hydralazine is the most well-studied time-dependent inhibitor (TDI) of AO and is frequently employed for AO reaction phenotyping in human hepatocytes to derive fm,AO, multiple studies have expressed concerns pertaining to its utility in providing accurate estimates of fm,AO values due to its propensity to significantly inhibit P450s at the concentrations typically utilized for reaction phenotyping. In this study, we characterized icotinib, a cyclized analogue of erlotinib, as a potent TDI of AO - inactivating human liver cytosolic zoniporide 2-oxidation equipotently with erlotinib with a kinact/KI ratioof 463 and 501 min-1mM-1, respectively. Moreover, icotinib also exhibits selectivity against P450 and elicits significantly weaker inhibition against human liver microsomal UGT1A1/3 as compared to erlotinib. Finally, we evaluated icotinib as an inhibitor of AO for reaction phenotyping in cryopreserved human hepatocytes and demonstrated that it can yield more accurate prediction of fm,AO compared to hydralazine and induce sustained suppression of AO activity at higher cell densities - which will be important for reaction phenotyping endeavors of low clearance drugs. Significance Statement In this study, we characterized icotinib as a potent time-dependent inhibitor of AO with ample selectivity margins against the P450s and UGT1A1/3 and demonstrated its utility for reaction phenotyping in human hepatocytes to obtain accurate estimates of fm,AO for victim DDI risk predictions. We envisage the adoption of icotinib in place of hydralazine in AO reaction phenotyping.Keywords
This publication has 42 references indexed in Scilit:
- Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotypingPharmacology & Therapeutics, 2021
- Aldehyde oxidase and its role as a drug metabolizing enzymePharmacology & Therapeutics, 2019
- Evaluation of Cytochrome P450 Selectivity for Hydralazine as an Aldehyde Oxidase Inhibitor for Reaction PhenotypingJournal of Pharmaceutical Sciences, 2019
- Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1Acta Pharmaceutica Sinica B, 2017
- Covalent inhibition of SUMO and ubiquitin-specific cysteine proteases by an in situ thiol–alkyne additionBioorganic & Medicinal Chemistry, 2013
- The pivotal role of hepatocytes in drug discoveryChemico-Biological Interactions, 2006
- Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administrationEuropean Journal of Cancer, 2002
- Synthesis and reactivity of a dimeric molybdenum(III) complex with a bridging hydrosulfido ligandJournal of the American Chemical Society, 1986
- Hydralazine: A potent inhibitor of aldehyde oxidase activity in vitro and in vivoBiochemical Pharmacology, 1985
- Kinetics of drug-drug interactionsJournal of Pharmacokinetics and Biopharmaceutics, 1973